2 days ago
DDB temporarily allows ordinary prescription for dangerous drugs
The Dangerous Drugs Board has allowed the temporary use of ordinary prescriptions for dangerous drugs under specific circumstances.
In a statement, the DDB said the move was done to improve access to essential treatment amid the ongoing threats posed by mpox, resurgence of COVID-19 cases, and rise in HIV infections, particularly among the youth.
Under Board Regulation No. 10, Series of 2025, licensed practitioners with an S2 license will be allowed to temporarily issue triplicate copies of ordinary prescriptions for medicines and pharmaceutical products containing dangerous drugs without the need for special yellow prescription forms from the Department of Health.
'This temporary regulatory flexibility is part of the government's broader response to ensure uninterrupted care for patients affected by these public health threats," said DDB Chairperson Secretary Oscar Valenzuela
"By easing prescription requirements for essential medications, we empower healthcare providers to deliver timely and essential treatments, especially in underserved communities,' he added.
The measure was conducted in line with the World Health Organization's standing recommendations under the International Health Regulations for improved access to regulated therapeutics, and as a response to the 500% increase in HIV reported among Filipino youths.
The regulation also issued specific guidelines on the content and handling of prescriptions, including prescription duration, conditions for multi-month prescriptions, responsibilities of dispensing pharmacists, and records management by prescribing physicians.
DDB said the safeguards are designed to balance accessibility with proper monitoring and accountability.
It added criminal and administrative sanctions under Republic Act No. 9165, or the Comprehensive Dangerous Drugs Act of 2002, remain in force to ensure that the temporary use of ordinary prescriptions will not be abused.
'We are reinforcing our commitment to public health while ensuring the proper oversight of controlled substances. This is a science-based, patient-centered policy that aligns with our duty to protect life while upholding the integrity of our drug control measures,' Valenzuela said.
The regulation will take effect 15 days after its publication and official registration, and will remain valid until June 30, 2026, unless repealed.—Jiselle Anne Casucian AOL, GMA Integrated News
